Luspatercept is the world's first and currently only red blood cell maturation agent which increases hemoglobin levels by promoting advanced red blood cell maturation.It's the first FDA-approved drug for beta-thalassemia.In January 2022,China's NMPA approved it for the treatment of adult beta-thalassemia patients who require regular red blood cell infusion and red blood cell infusion ≤ 15 units/24 weeks.Clinical studies have shown that luspatercept can effectively reduce blood transfusion burden in patients with beta-thalassemia with controllable adverse reactions and good tolerance.The mechanism,pharmacokinetics,clinical evaluation and safety are reviewed in this article so as to provide reference for clinical medication.
NETL
NSTL
万方数据
